Laid Bare By Coronavirus: China Starts To Fix A Huge But Fragile Health System
Changing Drug Access, Pricing, Coverage In Public Health Crisis
Shocking tales of people infected with the new coronavirus but who couldn’t get timely treatment due to lack of any or appropriate insurance have prompted fundamental changes in China’s health care system, with the government now trying to fix some notorious issues including payment before treatment.
You may also be interested in...
While many pharma firms rush to develop treatments or vaccines for the pandemic, some are quietly betting on digital health tools to bolster their business in post-coronavirus China.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.